Liquidia Corporation
Biotechnology, 419 Davis Dr, Morrisville, North Carolina, 27560, United States, 51-200 Employees
Phone Number: 91********
Who is LIQUIDIA CORPORATION
Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of...
Read More
-
Headquarters: 419 Davis Dr, Morrisville, North Carolina, 27560, United States
-
Date Founded: 2004
-
Employees: 51-200
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
-
CEO:
Roger Jeffs
Email
Phone
Industry: Biotechnology
SIC Code: 3841
|
NAICS Code: 541330 |
Show More
Does something look wrong? Fix it. | View contact records from LIQUIDIA CORPORATION
Liquidia Corporation Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Liquidia Corporation
Answer: Liquidia Corporation's headquarters are located at 419 Davis Dr, Morrisville, North Carolina, 27560, United States
Answer: Liquidia Corporation's phone number is 91********
Answer: Liquidia Corporation's official website is https://liquidia.com
Answer: Liquidia Corporation's revenue is $100 Million to $250 Million
Answer: Liquidia Corporation's SIC: 3841
Answer: Liquidia Corporation's NAICS: 541330
Answer: Liquidia Corporation has 51-200 employees
Answer: Liquidia Corporation is in Biotechnology
Answer: Liquidia Corporation contact info: Phone number: 91******** Website: https://liquidia.com
Answer: Liquidia is a biopharmaceutical company focused on the development and commercialization of products that address unmet patient needs, with current focus directed towards the treatment of pulmonary arterial hypertension (PAH). Our pipeline is focused on the development of two product candidates using our PRINT Technology platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Our subsidiary, Liquidia PAH (formerly RareGen), generates revenue pursuant to a promotional agreement between RareGen and Sandoz, sharing profit derived from the sale of the first-to-file fully substitutable generic treprostinil injection, or Treprostinil Injection, in the United States.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month